New cancer drug SBO-154 enters human testing for advanced tumors

NCT ID NCT07042100

Recruiting now Disease control Sponsor: Sun Pharma Advanced Research Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink tumors. Participants receive the drug by IV every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SBO-154 (a biologic drug given intravenously every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety, not proof of effectiveness. The drug may not shrink tumors or could cause side effects. Success is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

All India Institute for Medical Sciences
RECRUITING

Delhi, New Delhi, 110029, India

Contact Phone: •••-•••-•••• Email: •••••@•••••
Amrita Institute of Medical Sciences
NOT_YET_RECRUITING

Ernākulam, Kerala, 682041, India

Contact Phone: •••-•••-•••• Email: •••••@•••••
Cancer Research South Australia
RECRUITING

Adelaide, South Australia, 5000, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Honorhealth Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hope and Healing Clinical Research LLC
RECRUITING

Hinsdale, Illinois, 60521, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Kainos Super Speciality Hopsital
NOT_YET_RECRUITING

Rohtak, Haryana, 124001, India

Contact Phone: •••-•••-•••• Email: •••••@•••••
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Noble Hospital Pvt. Ltd.
RECRUITING

Pune, Maharashtra, 411013, India

Contact Phone: •••-•••-•••• Email: •••••@•••••
Pacific Medical College and Hospital
NOT_YET_RECRUITING

Udaipur, Rajasthan, 313001, India

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sarcoma Oncology Research Center
RECRUITING

Santa Monica, California, 90403, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, 2031, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sir H.N Reliance Foundation Hospital
NOT_YET_RECRUITING

Mumbai, Maharashtra, 400004, India

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sunshine Coast University Private Hospital
RECRUITING

Birtinya, Queensland, 4557, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Tata Memorial hospital
RECRUITING

Mumbai, Maharashtra, 400012, India

Contact Phone: •••-•••-•••• Email: •••••@•••••
Yale University - Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.